Visipaque Solution for Injection 270mg

Introduction

Visipaque is a prescription medication that contains the active ingredient Iodixanol. It is available in solution form and is commonly referred to by its generic name.

Uses

Visipaque is primarily used as a contrast agent during diagnostic imaging procedures, particularly in radiology and cardiology. It helps healthcare professionals obtain clear and accurate images of blood vessels, organs, and tissues by enhancing the visibility of these structures.

Dosage and Administration

The dosage of Visipaque will vary depending on the specific imaging procedure and individual patient factors. Follow the instructions provided by your healthcare provider or the package labeling. Visipaque is typically administered intravenously, meaning it is injected into a vein. The administration should be done by a healthcare professional in a controlled clinical setting.

Mechanism of Action

Visipaque works by altering the way X-rays or other imaging techniques interact with the body’s tissues and fluids. The active ingredient, Iodixanol, is a radiographic contrast agent that absorbs X-rays and helps highlight specific areas of interest during imaging procedures. This allows healthcare professionals to obtain clearer and more detailed images for accurate diagnosis and treatment planning.

Side Effects

Common side effects may include a warm or flushing sensation, nausea, vomiting, headache, or a metallic taste in the mouth. These side effects are usually mild and temporary. However, if you experience any severe or persistent side effects, such as difficulty breathing, chest pain, or swelling of the face or throat, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all medications, including over-the-counter drugs, supplements, and herbal remedies, that you are taking before using Visipaque. Certain medications may interact with Iodixanol and affect its effectiveness or increase the risk of side effects. Your healthcare provider will consider these potential interactions and make appropriate recommendations to ensure your safety during the imaging procedure.

Precautions

Before using Visipaque, inform your healthcare provider about any known allergies or sensitivities, especially to iodine-based contrast agents. Additionally, discuss any medical conditions you have, such as kidney problems, asthma, or a history of allergic reactions. Your healthcare provider will evaluate the potential risks and benefits of using Visipaque and determine if any precautions need to be taken.

Storage

Visipaque should be stored according to the instructions provided by the manufacturer or pharmacist. Typically, it should be stored at room temperature, away from direct sunlight, heat, and moisture. Keep it out of the reach of children and pets.

Patient Tips

• Follow all instructions provided by your healthcare provider regarding the use of Visipaque.
• Inform your healthcare provider about any medications, allergies, or medical conditions you have before using Visipaque.
• If you experience any unusual or concerning symptoms after receiving Visipaque, seek medical attention promptly.
• Keep track of any potential side effects you experience and report them to your healthcare provider.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• VISIPAQUE 270 mg I/ml Solution for Injection, glass container and polypropylene container (Health Professionals SmPC) Available at:
• Iodixanol (Drugs.com) [Accessed 2 Jun. 2024] (online) Available at:
• LactMed: Drugs and Lactation Database (National Library of Medicine) [Accessed 28 Jun. 2024] (online) Available at:
• Zhang J, Jiang Y, Rui Q, Chen M, Zhang N, Yang H, Zhou Y. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI. Medicine (Baltimore). 2018 May;97(18):e0617. doi: 10.1097/MD.0000000000010617. [Accessed 17 Jun. 2024] Available at: